Biphenyl Compounds Concept

subject area of

• A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours  Academic Article
• Acute Precipitants of Congestive Heart Failure Exacerbations  Academic Article
• Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk  Academic Article
• Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial  Academic Article
• Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction  Academic Article
• Albuminuria in chronic heart failure: prevalence and prognostic importance  Academic Article
• Antagonism of nociceptive responses of cat spinal dorsal horn neurons in vivo by the NK-1 receptor antagonists CP-96,345 and CP-99,994, but not by CP-96,344  Academic Article
• Antagonists of the serotonin receptor 5A target human breast tumor initiating cells  Academic Article
• Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial  Academic Article
• Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure  Academic Article
• Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction  Academic Article
• Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial  Academic Article
• Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme  Academic Article
• Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme  Academic Article
• Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease  Academic Article
• Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease  Academic Article
• Body Mass Index and Prognosis in Patients With Chronic Heart Failure  Academic Article
• CP-96,345, but not its stereoisomer, CP-96,344, blocks the nociceptive responses to intrathecally administered substance P and to noxious thermal and chemical stimuli in the rat  Academic Article
• Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough  Academic Article
• Candesartan for the management of heart failure: more than an alternative  Academic Article
• Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design  Academic Article
• Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways  Academic Article
• Characterization of excitatory prostanoid receptors in the human umbilical artery in vitro  Academic Article
• Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM  Academic Article
• Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response  Academic Article
• Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina  Academic Article
• Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure  Academic Article
• Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure  Academic Article
• Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program  Academic Article
• Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction  Academic Article
• Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme  Academic Article
• Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (I-PRESERVE) trial  Academic Article
• Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial  Academic Article
• Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure  Academic Article
• Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure  Academic Article
• Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure  Academic Article
• Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program  Academic Article
• Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction  Academic Article
• Differences in the Mechanisms of Proapoptotic BH3 Proteins Binding to Bcl-XL and Bcl-2 Quantified in Live MCF-7 Cells  Academic Article
• Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients  Academic Article
• Effect of Odanacatib on BMD and Fractures: Estimates from Bayesian Univariate and Bivariate Meta-analyses  Academic Article
• Effect of candesartan on New York Heart Association functional classResults of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure  Academic Article
• Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial  Academic Article
• Effects of blood pressure and lipid lowering on cognition  Academic Article
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial  Academic Article
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial  Academic Article
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial  Academic Article
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme  Academic Article
• Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker  Academic Article
• Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals  Academic Article
• Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart fa  Academic Article
• Electrophysiological Evidence That Neurokinin A Acts Via NK-1 Receptors in the Cat Dorsal Horn  Academic Article
• Enhanced activation of cellular AMPK by dual-small molecule treatment: AICAR and A769662  Academic Article
• Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction  Academic Article
• HR 720, a novel angiotensin receptor antagonist inhibits the angiotensin II-induced trophic effects, fibronectin release and fibronectin-EIIIA+ expression in rat aortic vascular smooth muscle cells in vitro.  Academic Article
• Hazard assessment using an in-silico toxicity assessment of the transformation products of boscalid, pyraclostrobin, fenbuconazole and glyphosate generated by exposure to an advanced oxidative process  Academic Article
• Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum  Academic Article
• Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial  Academic Article
• Homology modeling of Kv1.5 channel block by cationic and electroneutral ligands  Academic Article
• Hydrogen peroxide is an endothelium-dependent contracting factor in rat renal artery  Academic Article
• Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure  Academic Article
• Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study  Academic Article
• Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure  Academic Article
• Incidence and Predictors of Hyperkalemia in Patients With Heart Failure  Academic Article
• Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients  Academic Article
• Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure  Academic Article
• Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction  Academic Article
• Inhibitory prostanoid EP receptors in human non-pregnant myometrium  Academic Article
• Initial data supporting the design of the Candesartan in Heart failure — Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study  Academic Article
• Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET  Academic Article
• International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction  Academic Article
• Irbesartan in Patients with Atrial Fibrillation  Academic Article
• Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction  Academic Article
• Long-chain fatty acyl-CoA esters regulate metabolism via allosteric control of AMPK β1 isoforms  Academic Article
• Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial  Academic Article
• Mechanisms for perivascular adipose tissue-mediated potentiation of vascular contraction to perivascular neuronal stimulation: The role of adipocyte-derived angiotensin II  Academic Article
• Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction  Academic Article
• Monitoring the ACTIVE-W trial: Some issues in monitoring a noninferiority trial  Academic Article
• Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction  Academic Article
• Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W  Academic Article
• Myocardial Infarction in Heart Failure With Preserved Ejection Fraction  Academic Article
• Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics  Academic Article
• Novel substance P antagonist, CP-96,345, blocks responses of cat spinal dorsal horn neurons to noxious cutaneous stimulation and to substance P  Academic Article
• Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice  Academic Article
• Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction  Academic Article
• Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme  Academic Article
• Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme  Academic Article
• Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program  Academic Article
• Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.  Academic Article
• Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction  Academic Article
• Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction  Academic Article
• Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction  Academic Article
• Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program  Academic Article
• Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study  Academic Article
• Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors  Academic Article
• Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events  Academic Article
• Receptor subtypes mediating spinal cardiovascular effects of angiotensin II in rat using losartan and PD 123319  Academic Article
• Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure  Academic Article
• Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction  Academic Article
• Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure  Academic Article
• Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)  Academic Article
• Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial  Academic Article
• Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure  Academic Article
• Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure  Academic Article
• Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme  Academic Article
• Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk  Academic Article
• Sensory neuron and substance P involvement in symptoms of a zymosan-induced rat model of acute bowel inflammation  Academic Article
• Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction  Academic Article
• Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure  Academic Article
• Small Molecule Drug A-769662 and AMP Synergistically Activate Naive AMPK Independent of Upstream Kinase Signaling  Academic Article
• Structurally simplified biphenyl combretastatin A4 derivatives retain in vitro anti-cancer activity dependent on mitotic arrest  Academic Article
• Substance P released endogenously by high-intensity sensory stimulation potentiates purinergic inhibition of nociceptive dorsal horn neurons induced by peripheral vibration  Academic Article
• Substance-P-Mediated Intestinal Inflammation: Inhibitory Effects of CP 96,345 and SMS 201-995  Academic Article
• Tachykinin receptor antagonists inhibit hyperpnea-induced bronchoconstriction in guinea pigs.  Academic Article
• The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase  Academic Article
• The CHARM program: the effects of candesartan for the management of patients with chronic heart failure  Academic Article
• The CHARM programme  Academic Article
• The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial: Rationale and Design  Academic Article
• The NADPH oxidase inhibitor diphenyleneiodonium is also a potent inhibitor of cholinesterases and the internal Ca2+ pump  Academic Article
• The autophagy initiator ULK1 sensitizes AMPK to allosteric drugs  Academic Article
• The cost implication of primary prevention in the HOPE 3 trial  Academic Article
• Thienopyridone Drugs Are Selective Activators of AMP-Activated Protein Kinase β1-Containing Complexes  Academic Article
• Transgenic mice over-expressing substance P exhibit allodynia and hyperalgesia which are reversed by substance P and N-methyl-d-aspartate receptor antagonists  Academic Article
• Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both  Academic Article
• Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme  Academic Article
• Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment  Academic Article
• Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme  Academic Article